Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vale SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.34 (market cap $29.60B), while Vale SA trades at $14.5 (market cap $61.97B). The key difference: Vale SA is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Vale SA pays a 8.35% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VALE | |
|---|---|---|
Market Cap | $29.60B | $61.97B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $17.82 |
52-Week Low | $205.48 | $9.71 |
Enterprise Value | $27.56B | $78.22B |
Dividend Yield | — | 8.35% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
